The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial. On November 21, 2025, the FDA approved pembrolizumab (Keytruda) and pembrolizumab and berahyaluronidase alfa-pmph ...
YOLT-203 is an investigational gene-editing therapy for PH1, aiming to reduce oxalate overproduction by deactivating glycolate oxidase. The pivotal trial will assess YOLT-203's safety and efficacy in ...
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
At the 2025 LUGPA Annual Meeting, Jonathan Henderson, MD, delivered a talk titled, “Lessons Learned: Avoiding Pitfalls in Urology Practice Management.” During the meeting, Henderson sat down with ...
An expert discusses how KEYNOTE-905 establishes a new evidence-based systemic therapy option that transforms the management and prognosis of patients with muscle-invasive bladder cancer. The ...
A panel of experts discusses the evolution of BPH treatment, as well as how their practices have been affected by COVID-19.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback